Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Readout AI logo — Revolutionize clinical trial analysis with the power of AI

Readout AI

Revolutionize clinical trial analysis with the power of AI

Founded 2023 2 employees Pre Seed Total: $1.67M AI

General Information

Company Name Readout AI
Founded Year 2023
Employees 2
Industries AI
Funding Stage Pre Seed
Social

Get notified when Readout AI moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Readout AI

Readout AI is a startup that aims to revolutionize clinical trial analysis with the power of AI. Founded in 2023, the company has received a significant boost with a $1.67M Pre Seed Round investment on 14 July 2023 from noteworthy investors including Mucker Capital, Meridian Street Capital, Necessary Ventures, and Ryan Fukushima. The company's slogan, "Revolutionize clinical trial analysis with the power of AI," sums up its mission to transform the process of turning raw in-vivo and clinical trial data into actionable insights. Its platform allows users to upload trial data and employs AI algorithms to conduct appropriate statistical analyses, summarizing the results in tables, paragraphs, abstracts, plain-language summaries, or posters. This innovative approach drastically reduces the time and cost typically associated with data analysis in clinical trials, providing scientists with interpretable results in a matter of seconds. As an AI-focused company, Readout AI operates at the intersection of healthcare and technology, positioning itself as a game-changer in the field of clinical trial analysis.

Taxonomy: Clinical trials, Statistical analysis, In-vivo data, Cost reduction, Time efficiency, Scientific insights, Interpretable results, Research technology

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round •••••• 4
Investor Investor Investor
•••• •••• 		14 Jul 2023

Readout AI Alternatives & Competitors

Readout AI vs
Inspire Biotherapeutics Inc
Inspire Biotherapeutics Inc

Inspire is gene therapy platform company creating life-saving gene therapies for monogenic and acqui...

Pre Seed
1 employees
Biotechnology, Life Sciences
Readout AI vs
Stackoon.ai (TS Seattle '23)
Stackoon.ai (TS Seattle '23)

Manage Access & Licenses for 300,000 Tools

7 employees
Readout AI vs
StackBob (TS Seattle '23)
StackBob (TS Seattle '23) United States

Employee Access Management across 300,000 apps, even w/o SSO

Pre Seed
6 employees
Information Technology, SaaS

FAQ About Readout AI

Revolutionize clinical trial analysis with the power of AI
Readout AI was founded in 2023.
Readout AI operates in the following industries: AI.
Readout AI has approximately 2 employees.
Readout AI has completed 1 funding round, raising a total of $1.67M. The latest funding stage is Pre Seed.
Top alternatives and competitors to Readout AI include Inspire Biotherapeutics Inc, Stackoon.ai (TS Seattle '23), StackBob (TS Seattle '23), Chartrics, Cyrano Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Readout AI and Inspire Biotherapeutics Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Readout AI and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes